biomarkers
Early Detection of Pancreatic Cancer With Biomarkers Becoming a Reality
The early detection of pancreatic ductal adenocarcinoma may soon be realized, based on the accuracy of ...
AUGUST 15, 2025
Biomarkers Make Their Mark in Metastatic CRC
Advances in genetic testing are aiding in prognosis and therapeutic decision making in colorectal cancer.
OCTOBER 5, 2019
Are We Hitting the Mark With PD-L1 Biomarker Tests?
Denver—Potential hyperprogression and decreased survival in some patients taking checkpoint inhibitors, ...
AUGUST 15, 2018
Support for Biomarkers in Guiding Checkpoint Inhibitor Rx in NSCLC
Chicago—In the first-line treatment of NSCLC, new studies suggest that biomarkers for checkpoint ligand PD-L1 ...
AUGUST 9, 2018
Keytruda Approved for Any Solid Tumor With Specific Biomarker
Granted approval for the treatment of adult and pediatric patients with unresectable or metastatic solid ...
MAY 26, 2017
GHRH Receptor Can Confirm Prognosis, Offer Target
Growth hormone–releasing hormone receptor (GHRH-R) shows promise as a molecular target for gastric cancer ...
APRIL 5, 2017
Biomarker Score Helps Predict Recurrence in Clear Cell RCC
A new biomarker-based scoring system can help identify patients with clear cell renal cell carcinoma.
FEBRUARY 8, 2017
Cubilin Shows Promise for Diagnosing RCC
Swedish investigators have identified a protein they believe may aid in the differential diagnosis of renal cell ...
JANUARY 16, 2017
Atezolizumab Continues to Show Clinical Benefit in Advanced NSCLC
The immunotherapy atezolizumab demonstrated clinical benefit in advanced NSCLC in a study that extended the ...
DECEMBER 28, 2016
ERCC1 Protein An Ineffective Biomarker in Treatment of Advanced NSCLC
Patients with advanced squamous non-small cell lung cancer treated with platinum therapy had superior outcomes ...
DECEMBER 13, 2016
First Biomarker-Directed Therapy in SCLC Is Impressive
Chicago—Unprecedented response rates were achieved with a novel antibody drug conjugate for relapsed or ...
AUGUST 23, 2016
The Obstacle of the Nonresponder
Current research at NewYork-Presbyterian Hospital is focusing on immunotherapy and other strategies that use tumor ...
FEBRUARY 1, 2016
